ICTH - Subcommittee on Clinical Trials: Registry of Multicenter Clinical Trials

References
1 Verstraete M. Registry of prospective clinical trials. First report. Thrombos Diathes Haemorrh 1975; 33: 655-663
2 Verstraete M. Registry of prospective clinical trials. Second report. Thromb Haemostas 1976; 36: 239-250
3 Verstraete M. Registry of prospective clinical trials. Third report. Thromb Haemostas 1978; 39: 759-767
4 Verstraete M. Registry of prospective clinical trials. Fourth report. Thromb Haemostas 1980; 43: 176-181
5 Verstraete M. Registry of prospective clinical trials. Fifth report. Thromb Haemostas 1982; 48: 334-338
6 Verstraete M. Registry of prospective clinical trials. Sixth report. Thromb Haemostas 1984; 51: 283-290
7 Leizorovicz A, Boissel JP. Oral Anticoagulant in Patients Surviving Myocardial Infarction: a New Approach for Old Data. Eur J Clin Pharmacol 1983; 24: 333-336
8 Rentrop KP et al. Effects of Intracoronary Streptokinase and Intracoronary Nitroglycerin Infusion on Coronary Angiographic Patterns and Mortality in Patients with Acute Myocardial Infarction. N Engl J Med 1985; 311: 1457-1463
9 TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial. Phases I findings. N Engl J Med 1985; 312: 932-936
10 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, DeBono DP, Erbel R, Huchmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michelsy HR, Rutsch W, Schartl M, Schmidt W, Uebis R, Von Essen R. Randomized Trial of Intravenous Recombinant Tissue-type Plasminogen Activator versus Intravenous Streptokinase in Acute Myocardial Infarction. Lancet 1985; 1: 842-847
11 Freiman JA, Chalmers TC, Smith H, Kuebler R. The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Controlled Trial. N Engl J Med 1978; 299: 690-694
12 Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction: a 12-month Follow-up Report. N Engl J Med 1985; 312: 1073-1078
13 Chesebro JM et al. A Platelet-Inhibitor-Drug Trial in Coronary Artery By-Pass Operations: Benefit of Perioperative Dipyridamole and Aspirin Therapy on Early Post-Operative Vein-Graft Patency. N Engl J Med 1982; 307: 73-78
14 WHO. Cooperative Trial on Primary Prevention of Ischemic Heart Disease Using Clofibrate to Lower Serum Cholesterol: Mortality Follow-Up: Report of the Committee of Principal Investigators. Lancet 1980; 2: 379-385
15 The Coronary Drug Project Group. Clofibrate and Niacin in Coronary Heart Disease. JAMA 1975; 231: 360-380
16 Hess H, Mietaschk A, Deichsel G. Drug-Induced Inhibition of Platelet Function Delays Progression of Peripheral Occlusive Arterial Disease; a Double-Blind Arteriographically Controlled Trial. Lancet 1985; 1: 415-419
17 Bulkley BH, Hutchins GM. Accelerated “A1therosclerosis” a Morphologic Study of 97 Saphenous Vein Coronary Artery Bypass Grafts. Circulation 1977; 55: 163-169
18 Campeau L, Enjalbert M, Lesperance J, Bourassa M, Kwiterovitch P, Walcholder S, Sniderman A. The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native Circulation; a Study 10 Years after Aortocoronary Bypass Surgery. N Engl J Med 1984; 311: 1329-1332